The Valley Desk

NCT05555589 · Interventional trial

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Overall registry status Completed

Phase 3

Conditions Neurotrophic Keratopathy

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov